
Bylenta MCH 12.5mg/50mg/40mg Tablet
Marketer
Lloyd Healthcare Pvt Ltd
Salt Composition
Chlorthalidone (12.5mg) + Metoprolol Succinate (50mg) + Telmisartan (40mg)
Overview Bylenta MCH 12.5mg/50mg/40mg Tablet
CardioTrio HT 12.5mg/50mg/40mg tablets are a triple-action medication prescribed for hypertension management. This formulation lowers blood pressure by promoting vasodilation and enhancing cardiac output. It also facilitates diuresis, eliminating excess fluid and electrolytes. CardioTrio HT may be ingested with or without food, but consistent timing optimizes efficacy. Its diuretic effect may necessitate daytime administration, ideally at least four hours prior to sleep, to minimize nocturnal urination. Dosage and frequency are determined by your physician, based on individual needs and treatment goals. Continuous use, as directed, is crucial. Commonly reported side effects include nausea, altered taste perception, diarrhea, and gastrointestinal discomfort. Regular monitoring of renal function and electrolyte levels is essential. Optimal results are achieved when combined with lifestyle modifications such as a balanced diet, regular physical activity, and smoking cessation. Increased fluid intake is recommended to counteract potential dryness of the mouth and thirst. Prior to commencing treatment, inform your doctor of any pregnancy, circulatory disorders, hepatic or renal impairments, and all other medications currently being used, as interactions may influence the drug's effectiveness or mechanism of action.
Uses of Bylenta MCH 12.5mg/50mg/40mg Tablet
Elevated blood pressure
Major Benefits of Bylenta MCH 12.5mg/50mg/40mg Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Bylenta MCH 12.5mg/50mg/40mg Tablet whole; avoid chewing, crushing, or breaking it. This medication can be administered with or without food, however, consistent daily timing is recommended.
Common Side effects of Bylenta MCH 12.5mg/50mg/40mg Tablet:
- Nausea
- Taste change
- Diarrhea
- Upset stomach
- Headache
- Dizziness
- Weakness
- Cold extremities
- Numbness of extremity
- Increased uric acid level in blood
- Increased blood lipid level
- Decreased magnesium level in blood
- Slow heart rate
- Decreased sodium level in blood
- Decreased blood pressure
How to use Bylenta MCH 12.5mg/50mg/40mg Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Bylenta MCH 12.5mg/50mg/40mg tablets can be consumed with or without food, although consistent timing is recommended.
How Bylenta MCH 12.5mg/50mg/40mg Tablet works:
Each Bylenta MCH tablet (12.5mg/50mg/40mg chlorthalidone/metoprolol succinate/telmisartan) combines three blood pressure-reducing medications for effective hypertension management.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol alongside Bylenta MCH 12.5mg/50mg/40mg Tablet is not advisable.
PregnancyCONSULT YOUR DOCTOR
Use of Bylenta MCH 12.5mg/50mg/40mg tablets is contraindicated during pregnancy due to established fetal risks. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is essential.
Breast feedingSAFE IF PRESCRIBED
Lactation compatibility of Bylenta MCH 12.5mg/50mg/40mg tablets is likely favorable. Available human data indicate minimal infant risk associated with maternal use.
DrivingUNSAFE
Taking Bylenta MCH 12.5mg/50mg/40mg tablets might reduce alertness, impair vision, and cause drowsiness or dizziness. Refrain from driving if you experience these effects.
KidneyCAUTION
Patients with severe kidney impairment should use Bylenta MCH 12.5mg/50mg/40mg tablets cautiously, potentially requiring dosage modification. Physician consultation is advised. The use of Bylenta MCH 12.5mg/50mg/40mg tablets is contraindicated in such cases.
LiverCAUTION
Patients with liver impairment should use Bylenta MCH 12.5mg/50mg/40mg tablets cautiously, potentially requiring dosage modification. Physician consultation is advised. The use of Bylenta MCH 12.5mg/50mg/40mg tablets is contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take Bylenta MCH 12.5mg/50mg/40mg Tablet :
Should you forget to take your Bylenta MCH 12.5mg/50mg/40mg Tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Bylenta MCH 12.5mg/50mg/40mg Tablet
| Label | Value |
|---|---|
| Developing Good Habits | No. |
| Treatment Category | Heart |
